RXi Pharmaceuticals is a biotechnology company engaged in the discovery, development and commercialization of innovative therapies to address major unmet medical needs using RNA-targeted technologies. Building on the groundbreaking work of Nobel Laureate and RXi Scientific Advisory Board member Dr. Craig Mello, the company’s first product candidate, RXI-109, entered into human clinical development in June of 2012. For more information, visit the company’s Web site at www.rxipharma.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: